Drug alleviates memory problems, confusion and aggression (illustration)
Photo: CD Bank
Teva gets OK for generic Alzheimer's drug
US Food and Drug Administration allows Israel-based drugmaker to sell generic version of Aricept, jointly marketed by Pfizer and Eisai
The US Food and Drug Administration has approved Teva Pharmaceutical Industries Ltd. to sell a generic version of blockbuster Alzheimer's drug Aricept.
Significant Results
Eli Shimony
Israeli drug maker's portfolio company CureTech announces preliminary topline results for investigational anti-PD-1 monoclonal antibody
Aricept is jointly marketed by New York-based Pfizer Inc. and Japanese drugmaker Eisai Co. Ltd.
Jerusalem-based Teva said Wednesday that it has already begun shipping the product, in 5 milligram and 10 milligram tablets.
Sales of brand-name and generic Aricept total about $2.3 billion in the United States, according to Teva.
Pfizer reported $417 million in revenue from Aricept in 2010, but noted it lost exclusivity for the drug in November.
Aricept had been the market leader among drugs that alleviate symptoms of Alzheimer's disease, such as memory problems, confusion and aggression.
- Follow Ynetnews on Facebook
